Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination
Source abstract
Abstract
ABSTRACT Vaccine approaches capable of eliciting enhanced germinal center (GC) responses would result in improved protective humoral immunity against infectious diseases. Here, we investigate whether a cytokine can be scaffolded onto a self‐assembling nanoparticle immunogen to enhance antigen‐specific GC responses and B cell maturation. To test this approach, we design chimeric nanoparticles bearing eOD‐GT8, a germline‐targeting HIV immunogen, and IL‐21, a canonical GC cytokine. DNA delivery of these nanoparticle immunoadjuvant complexes (GT8‐IL‐21‐NICs) drives improved serum antibody titers and antigen‐specific GC B cell responses in mice. Transcriptomic analysis of eOD‐GT8‐specific GC B cells demonstrates upregulation of selection‐associated gene signatures with GT8‐IL‐21‐NIC immunization. In mice harboring human bnAb precursor heavy and light chain genes, immunization with the GT8‐IL‐21‐NIC leads to increased antibody diversity, clonal expansion, somatic hypermutation, and the acquisition of key antibody mutations. These results highlight IL‐21 as a promising genetic adjuvant and demonstrate that NICs may be a valuable tool to improve antigen‐specific GC responses and vaccine‐induced immunity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · HIV Research and Treatment · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Vaccine and Immunotherapy Centerthe Wistar Institute Philadelphia Pennsylvania USA
Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
Biology Department Saint Joseph's University Philadelphia Pennsylvania USA
Division of Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York New York USA
Funding
National Science Foundation · INOVIO Pharmaceuticals
References (86)
Show source-provided references
1. 10.1146/annurev-immunol-120419-02240810.1146/annurev-immunol-120419-022408 ↗
2. 10.3389/fimmu.2021.66167810.3389/fimmu.2021.661678 ↗
3. 10.1016/j.immuni.2014.10.00410.1016/j.immuni.2014.10.004 ↗
4. 10.1016/j.immuni.2019.04.01110.1016/j.immuni.2019.04.011 ↗
5. 10.1038/ni.242810.1038/ni.2428 ↗
6. 10.3390/antib501000510.3390/antib5010005 ↗
7. 10.1084/jem.2009177710.1084/jem.20091777 ↗
8. 10.1016/j.immuni.2022.06.02010.1016/j.immuni.2022.06.020 ↗
9. 10.1016/j.immuni.2021.08.02810.1016/j.immuni.2021.08.028 ↗
10. 10.1016/j.immuni.2024.02.01810.1016/j.immuni.2024.02.018 ↗
11. 10.1126/science.aac589410.1126/science.aac5894 ↗
12. 10.1016/j.cell.2016.07.03010.1016/j.cell.2016.07.030 ↗
13. 10.1126/science.aax438010.1126/science.aax4380 ↗
14. 10.1126/sciimmunol.adk955010.1126/sciimmunol.adk9550 ↗
15. 10.1038/s41590-024-01833-w10.1038/s41590-024-01833-w ↗
16. 10.1126/science.add650210.1126/science.add6502 ↗
17. 10.1126/science.adr838210.1126/science.adr8382 ↗
18. 10.1126/science.aad919510.1126/science.aad9195 ↗
19. 10.1016/j.immuni.2022.09.00110.1016/j.immuni.2022.09.001 ↗
20. Deep Mining of the Human Antibody Repertoire Identifies Frequent and Immunogenetically Diverse CDRH3 Topologies Targetable by Vaccination
21. 10.1016/j.immuni.2020.08.00110.1016/j.immuni.2020.08.001 ↗
22. Antigen Avidity Drives the Durability of the Vaccine Immune Response
23. 10.1080/14760584.2019.157821610.1080/14760584.2019.1578216 ↗
24. 10.1021/cb600489g10.1021/cb600489g ↗
25. 10.1016/j.celrep.2016.04.07810.1016/j.celrep.2016.04.078 ↗
26. 10.1002/advs.20190280210.1002/advs.201902802 ↗
27. 10.1158/2326-6066.CIR-20-006110.1158/2326-6066.CIR-20-0061 ↗
28. 10.1016/j.celrep.2022.11031810.1016/j.celrep.2022.110318 ↗
29. 10.3389/fimmu.2023.107281010.3389/fimmu.2023.1072810 ↗
30. 10.1002/wnan.188010.1002/wnan.1880 ↗
31. 10.1016/j.vaccine.2020.03.04710.1016/j.vaccine.2020.03.047 ↗
32. 10.1016/j.xcrm.2022.10069310.1016/j.xcrm.2022.100693 ↗
33. 10.3389/fimmu.2023.113860910.3389/fimmu.2023.1138609 ↗
34. 10.1172/jci.insight.13707910.1172/jci.insight.137079 ↗
35. 10.1126/sciimmunol.ads132810.1126/sciimmunol.ads1328 ↗
36. 10.15252/embr.20225467710.15252/embr.202254677 ↗
37. 10.1038/ncomms1464710.1038/ncomms14647 ↗
38. 10.1038/ni110010.1038/ni1100 ↗
39. 10.1038/nri380410.1038/nri3804 ↗
40. 10.1016/j.immuni.2007.07.00910.1016/j.immuni.2007.07.009 ↗
41. 10.1016/j.celrep.2021.10996110.1016/j.celrep.2021.109961 ↗
42. R. P.Staupe L. A.Vella S.Manne et al. “Chronic viral infection promotes early germinal center exit of B cells and impaired antibody development” (2019) https://doi.org/10.1101/849844.10.1101/849844 ↗
43. 10.1016/j.cell.2010.10.03210.1016/j.cell.2010.10.032 ↗
44. 10.1182/blood-2012-03-41538010.1182/blood-2012-03-415380 ↗
45. 10.1093/intimm/dxad01710.1093/intimm/dxad017 ↗
46. 10.7554/eLife.5985010.7554/eLife.59850 ↗
47. 10.1038/ni135710.1038/ni1357 ↗
48. 10.3389/fimmu.2021.70584810.3389/fimmu.2021.705848 ↗
49. 10.1073/pnas.190125811610.1073/pnas.1901258116 ↗
50. 10.1038/s41577-020-00446-210.1038/s41577-020-00446-2 ↗
51. 10.1182/blood.201888013810.1182/blood.2018880138 ↗
52. 10.4049/jimmunol.150049710.4049/jimmunol.1500497 ↗
53. 10.1111/j.1600-065X.2009.00782.x10.1111/j.1600-065X.2009.00782.x ↗
54. 10.1016/j.celrep.2023.11251210.1016/j.celrep.2023.112512 ↗
55. 10.1016/j.immuni.2015.10.02110.1016/j.immuni.2015.10.021 ↗
56. 10.26508/lsa.20190050610.26508/lsa.201900506 ↗
57. 10.1084/jem.2016126310.1084/jem.20161263 ↗
58. 10.1084/jem.2020169910.1084/jem.20201699 ↗
59. 10.1126/science.119281910.1126/science.1192819 ↗
60. 10.1126/science.120753210.1126/science.1207532 ↗
61. 10.1126/science.120722710.1126/science.1207227 ↗
62. 10.1073/pnas.120898410910.1073/pnas.1208984109 ↗
63. 10.1073/pnas.221788312010.1073/pnas.2217883120 ↗
64. 10.1126/scitranslmed.adn022310.1126/scitranslmed.adn0223 ↗
65. 10.1038/s41586-019-1250-z10.1038/s41586-019-1250-z ↗
66. 10.1016/j.cell.2016.08.00510.1016/j.cell.2016.08.005 ↗
67. 10.1038/s41541-024-00971-410.1038/s41541-024-00971-4 ↗
68. 10.1016/j.cell.2025.07.00910.1016/j.cell.2025.07.009 ↗
69. 10.1038/s41590-022-01163-910.1038/s41590-022-01163-9 ↗
70. 10.1016/j.immuni.2020.11.00910.1016/j.immuni.2020.11.009 ↗
71. 10.1038/s41467-021-27477-010.1038/s41467-021-27477-0 ↗
72. 10.1038/s41467-022-33309-610.1038/s41467-022-33309-6 ↗
73. 10.1016/j.immuni.2008.06.00110.1016/j.immuni.2008.06.001 ↗
74. 10.4049/jimmunol.150146310.4049/jimmunol.1501463 ↗
75. 10.1016/j.it.2016.06.00110.1016/j.it.2016.06.001 ↗
76. 10.1016/j.immuni.2019.06.01310.1016/j.immuni.2019.06.013 ↗
77. 10.1038/ni.241810.1038/ni.2418 ↗
78. 10.1016/j.immuni.2005.09.01310.1016/j.immuni.2005.09.013 ↗
79. 10.1126/science.112570310.1126/science.1125703 ↗
80. 10.1016/j.xcrm.2025.10203510.1016/j.xcrm.2025.102035 ↗
81. 10.1038/s41586-021-03819-210.1038/s41586-021-03819-2 ↗
82. 10.1038/s41586-024-07487-w10.1038/s41586-024-07487-w ↗
83. 10.1038/s41592-022-01488-110.1038/s41592-022-01488-1 ↗
84. 10.1016/j.cell.2021.04.04810.1016/j.cell.2021.04.048 ↗
85. 10.1038/s41590-018-0276-y10.1038/s41590-018-0276-y ↗
86. 10.1186/s12864-018-4772-010.1186/s12864-018-4772-0 ↗